Fierce Pharma

MARCH 7, 2024

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

Sales 241

Sales 241

Fierce Pharma

SEPTEMBER 5, 2023

The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026.

Biopharma 303

Biopharma Government 303

Fierce Pharma

SEPTEMBER 12, 2023

28, 2026. The deal clears “all pending claims” and tees up a potential Dasynoc launch on Sept. 1, 2024, or potentially earlier under certain circumstances. The Sprycel patents in question aren’t due to expire until Sept.

FDA 287

FDA Pharma 287

Fierce Pharma

OCTOBER 9, 2023

billion) for exclusive rights to distribute the shingles shot in China from 2024 through 2026. GSK has forged a partnership with vaccine powerhouse Chongqing | GSK has forged a partnership with vaccine powerhouse Chongqing Zhifei Biological Products to distribute Shingrix in China. Zhifei will pay £2.5 billion ($3.05

Distribution 287

Distribution 287

Fierce Pharma

OCTOBER 27, 2023

In August, Imbruvica was one of the 10 drugs identified by the CMS that will be subject to price negotiations in 2026. . | Sales of AbbVie and Johnson & Johnson’s leukemia blockbuster Imbruvica are taking a hit from BeiGene’s Brukinsa. But what about the impact of the Inflation Reduction Act?

Sales 271

Sales 271

Fierce Pharma

DECEMBER 14, 2023

Ahead of 2026’s Medicare drug price negotiations, the White House is getting ready to crack down on companies who’ve raised the costs of their medications faster than the rate of inflation.

Medical 225

Medical 225

MedCity News

MAY 15, 2023

The royalty deal extends uniQure’s cash runway into 2026. By selling partial royalties to approved hemophilia gene therapy Hemgenix, uniQure gains immediate cash to support its pipeline, including a Huntington’s disease gene therapy already in the clinic.

Biopharma 110

Biopharma Pharma 110

PharmaTech

SEPTEMBER 15, 2023

According to a press release, the implications go to the extent that within the next 10 years, more than 50% of approved drugs will involve AI in their development and/or manufacturing.

Manufacturing 52

Manufacturing 52

Pharmaceutical Technology

NOVEMBER 8, 2023

The company’s cash reduction measures are expected to extend its cash runway into 2026.

64

64

PharmExec

AUGUST 29, 2023

Lawsuit comes amid announcement of the first 10 drugs eligible for negotiated prices in 2026.

98

98

Pharmaceutical Technology

JULY 20, 2023

The centre is planned for completion in 2026, along with plans to build a $400m biologics manufacturing plant.

Manufacturing 74

Manufacturing 74

Scott Burrows

JULY 5, 2022

By 2026, industry experts expect EV sales to quadruple from 2020,… As an insurance and financial speaker with strong ties to the industry, I have not seen such interesting—and positive—developments in years. For example, according to Statista the sales of electric vehicles are on the verge of explosion.

Insurance 98

Insurance Sales 98

Clear Pivot

SEPTEMBER 22, 2022

billion by 2026 , so take the steps to create a successful medtech marketing strategy now as the industry is still growing. However, while your product is the backbone of your success, you must also successfully market it to buyers. Revenue from the medical technology industry is projected to reach $644.20

Marketing 89

Marketing Competition Medical Healthcare 89

Pharmaceutical Technology

SEPTEMBER 23, 2022

It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Additionally, Merck has signed patent litigation settlement deals with various generic firms, permitting them to offer generic versions of Januvia and Janumet to the US market in May 2026, or before under specific conditions.

Food and Drug Administration 69

Food and Drug Administration FDA Food Marketing 69

European Pharmaceutical Review

JULY 10, 2023

billion in 2026. Given their short shelf-life, there is a need for methods that generate more rapid results for emerging advanced therapy medicinal products (ATMPs) such as cell and gene therapies. Currently, there are more than 2,000 active clinical trials for cell and gene therapies, 1 with the market expected to grow from $8.6

Pharmaceutical products 91

Pharmaceutical products Manufacturing Medicine Pharmaceutical 91

pharmaphorum

SEPTEMBER 30, 2022

That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No. Viatris could still take its cases further, but for now Merck has retained market exclusivity for Januvia, Janumet, and Janumet XR until at least 2026.

Marketing 57

Marketing Sales Competition FDA 57

Pharmacy Times

AUGUST 30, 2023

Any new prices established after negotiations will be effective on January 1, 2026.

52

52

European Pharmaceutical Review

FEBRUARY 5, 2024

Novo Nordisk specified that the transaction is expected to support an incremental increase in the company’s filling capacity from 2026 and onwards. Increasing capacity Acquisition of the three sites will enable the manufacturing capacity to be expanded at scale and speed.

Manufacturing 95

Manufacturing Networking Pharmaceutical 95

Clarify Health

APRIL 26, 2022

health system realize $150 billion in savings by 2026. Artificial intelligence (AI) has the potential to affect healthcare in profound ways — propelling better data-driven decisions on diagnoses, treatments, and population health management. Reports indicate that AI can help the U.S.

Healthcare 59

Healthcare Healthcare Management Healthcare Provider 59

European Pharmaceutical Review

DECEMBER 12, 2023

The centre, which will create up to 330 new jobs in the region, is expected to be operational by the end of 2026. The new biosimilars production centre will also include facilities for manufacturing and storage.

Pharmaceutical 96

Pharmaceutical Manufacturing Medicine 96

European Pharmaceutical Review

NOVEMBER 24, 2023

These activities are expected to be completed incrementally between 2026 to 2028, the company stated. While the current production facility in Chartres, France, employ around 1,600 people, once the new multi-product facilities are in operation, over 500 new jobs will be created to manage continuous production activities.

Manufacturing 97

Manufacturing Pharmaceutical manufacturing Pharmaceutical Medicine 97

PharmaTech

JANUARY 2, 2023

This compilation allows readers to adjust their thinking to appreciate the full impact certain select technologies will make on the industry by 2026.

52

52

Pharmaceutical Technology

APRIL 19, 2023

Camlipixant is being assessed in the CALM Phase III clinical development programme, with anticipated regulatory approval and launch in 2026. The company will gain access to BELLUS’s investigational, twice-daily oral P2X3 receptor antagonist, camlipixant, to treat refractory chronic cough (RCC).

Specialization 97

Specialization Medicine Sales Patients 97

European Pharmaceutical Review

SEPTEMBER 22, 2023

Research Nester highlighted statistics which acknowledged that European production of pharmaceutical aseptic packaging is expected to reach $56 billion by 2026. Growth of the European aseptic packaging market The pharmaceutical industry in Europe is witnessing growth in the market for aseptic packaging. percent annually in recent years.

Marketing 91

Marketing Distribution Pharmaceutical Safety 91

Pharmaceutical Technology

JUNE 2, 2023

More significantly, the revised contract secures about 70 million vaccine doses every year from 2023 to 2026 for member states, leaving little space in the market for competitors. This deal, therefore, serves as a threat to other vaccine developers with authorisations for distribution in the EU, including Moderna, Novavax, and Sanofi.

Leads 52

Leads Safety Distribution Marketing 52

European Pharmaceutical Review

OCTOBER 4, 2023

Sandoz – advancing biosimilar development in Europe Prior to the proposed spin-off being actioned, Sandoz announced in July 2023 that it planned to invest approximately $90 million to build a Biosimilar Technical Development Center in Slovenia by 2026.

CRM 95

CRM Medicine Competition Pharmaceutical 95

European Pharmaceutical Review

JULY 21, 2023

The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. To support future growth of its biosimilar pipeline, Sandoz is planning to build a Biosimilar Technical Development Center in Slovenia.

Biopharma 93

Biopharma Manufacturing Competition Healthcare 93

European Pharmaceutical Review

APRIL 15, 2024

Anticipating a positive Phase III outcome and a potential commercial launch in 2026, we aim to capture a substantial share of the market for third-line patients, thereby marking a turning point in the management of this condition,” Affagard added.

Pharma 56

Pharma Patients Management Leads 56

European Pharmaceutical Review

DECEMBER 22, 2023

Registrational clinical trials are currently underway evaluating KarXT for the treatment of Alzheimer’s disease psychosis, with data expected in 2026. “KarXT also has the potential to deliver meaningful benefits to patients…as a first treatment for Alzheimer’s disease psychosis,” Hirawat added.

Food and Drug Administration 96

Food and Drug Administration Side effects Safety Food 96

Pharmaceutical Technology

JULY 26, 2022

This pro forma cash balance of nearly $470m is anticipated to offer a cash runway for the merged company through 2026. It will take the total pro forma cash balance of the merged business to a minimum of $470m apart from a total enterprise value of $326m.

Pharma 59

Pharma Specialization Healthcare Healthcare 59

European Pharmaceutical Review

JULY 6, 2023

Further trials will be launching although most patients are expected to be enrolled from 2026 onwards. Deemed a “landmark new agreement” by UK Prime Minister Rishi Sunak, the UK-based clinical trials will focus on personalised mRNA-based cancer immunotherapies. BioNTech SE has already begun conducting clinical trials in the UK.

Government 92

Government Patients Pharmaceutical 92

Pharmaceutical Commerce

JULY 6, 2022

With a cost of approximately $514 million, expected completion is 2026.

52

52

European Pharmaceutical Review

MARCH 13, 2023

Full operations is provisionally planned for late 2026. Signing of the MOU “sets up Sandoz to expand patients’ access to the large number of biologics losing patent protection over the next few years,” commented Dominic Wake, Head of Market Access and Corporate Affairs at Sandoz.

Networking 82

Networking Competition Pharma Pharmaceutical 82

European Pharmaceutical Review

SEPTEMBER 11, 2023

This move would help to establish its Sandoz Biopharma Development Center by 2026, the company stated when the news was announced. In July 2023, Sandoz revealed that to support future development of its biosimilar pipeline, it planned to invest approximately $90 million at its site in Ljubljana, Slovenia.

Biopharma 77

Biopharma Manufacturing Medicine Safety 77

Pharmaceutical Technology

MAY 11, 2023

To further understand GlobalData's analysis on Internet of Things (IoT) Market Size, Share, Trends Analysis, and Segment Forecast 2021-2026 buy the report here. GlobalData identified 401 internet of things-related posts in the industry's social media activity - 0.03% of all posts - and a decrease of 9% in Q1 2023 compared with Q4 2022.

Media 52

Media Pharma Competition Marketing 52

Pharmaceutical Technology

APRIL 10, 2023

Under the deal, Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026. India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with Swiss drugmaker Novartis Pharma for the diabetes drug Galvus and its combination brands.

Manufacturing 52

Manufacturing Medicine Pharma Sales 52

European Pharmaceutical Review

NOVEMBER 15, 2023

In July, Sandoz shared that it planned to invest approximately $90 million at its European site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. The company stated that the new site will create approximately 200 new full-time jobs once the facility is opened.

Medicine 70

Medicine Manufacturing Networking Biopharma 70